Literature DB >> 11343992

Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease.

H Komai1, Y Naito, Y Aimi, H Kimura.   

Abstract

Since little is known about the contribution of endothelial nitric oxide synthase (e-NOS) to the mechanism of pulmonary vasospasm and the development of pulmonary vascular occlusive disease, we elucidate how e-NOS is expressed in lung biopsy specimens obtained from operative patients with pulmonary hypertension. Lung biopsy specimens were obtained from 17 patients who underwent open-heart operations for various heart diseases. A piece of normal lung specimen was also obtained from the resected lungs of three lung cancer patients as a control. e-NOS expression was visualized with a monoclonal antibody against e-NOS, and the level of expression was partially quantified. Significantly high levels of e-NOS expression were seen in adult patients, whose preoperative mean pulmonary arterial pressures were greater than 20 mm Hg. In contrast, e-NOS expression in pediatric patients with the same levels of mean pulmonary arterial pressure was the same as that in the controls and in low pulmonary arterial pressure. There was a statistically significant positive correlation between the level of e-NOS expression and Heath--Edwards grading. These data suggest that the e-NOS expression in lung tissue is induced when pulmonary vascular obstructive diseases progress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343992     DOI: 10.1016/s1054-8807(00)00063-6

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  5 in total

1.  Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.

Authors:  Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin
Journal:  Eur J Pediatr       Date:  2010-12-01       Impact factor: 3.183

2.  Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow.

Authors:  Kan Puikuan; Zhang Chunyu; Fan Jin; Tang Chaoshu; Du Junbao
Journal:  Heart Vessels       Date:  2006-05       Impact factor: 2.037

3.  Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Authors:  Hee Sun Koo; Kwan Chang Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2011-02-28       Impact factor: 3.243

4.  Hypoxia Triggers SENP1 (Sentrin-Specific Protease 1) Modulation of KLF15 (Kruppel-Like Factor 15) and Transcriptional Regulation of Arg2 (Arginase 2) in Pulmonary Endothelium.

Authors:  Deepesh Pandey; Yohei Nomura; Max C Rossberg; Daijiro Hori; Anil Bhatta; Gizem Keceli; Thorsten Leucker; Lakshmi Santhanam; Larissa A Shimoda; Dan Berkowitz; Lewis Romer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-22       Impact factor: 8.311

5.  Κ-opioid receptor stimulation improves endothelial function in hypoxic pulmonary hypertension.

Authors:  Qi Wu; Hai-Yan Wang; Juan Li; Peng Zhou; Qiu-Lin Wang; Lei Zhao; Rong Fan; Yue-Min Wang; Xue-Zeng Xu; Ding-Hua Yi; Shi-Qiang Yu; Jian-Ming Pei
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.